Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials? | Zendy

Sarah A. Holstein | Zendy; Vera J. Suman | Zendy; Philip L. McCarthy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?

Author(s) -

Sarah A. Holstein,

Vera J. Suman,

Philip L. McCarthy

Publication year - 2019

Publication title -

current hematologic malignancy reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.299

H-Index - 35

eISSN - 1558-822X

pISSN - 1558-8211

DOI - 10.1007/s11899-019-0495-9

Subject(s) - clinical endpoint , medicine , multiple myeloma , surrogate endpoint , clinical trial , randomized controlled trial , progression free survival , oncology , hematology , overall survival , clinical study design , intensive care medicine

While the traditional gold standard for demonstrating clinical benefit of a therapy has been to show prolongation of overall survival (OS), there are multiple factors which can hinder the use of OS as a primary endpoint in randomized clinical trials (RCTs). Here, we analyze recent myeloma RCTs and evaluate the issues relevant to current and future myeloma RCT design.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research